Last update 28 Jun 2025

CAR transduced autologous T cells targeting CD19/CD20(JW Therapeutics)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
JWCAR-239
Target
CD19 x CD20
Action
modulators
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), CD20 modulators(B-lymphocyte antigen CD20 modulators)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Diffuse Large B-Cell LymphomaMantle-Cell LymphomaMarginal Zone B-Cell Lymphoma+ [1]
Inactive Indication-
Originator Organization
JW Therapeutics (Shanghai) Co., Ltd.JW Therapeutics (Shanghai) Co., Ltd.
Active Organization
JW Therapeutics (Shanghai) Co., Ltd.JW Therapeutics (Shanghai) Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with CAR transduced autologous T cells targeting CD19/CD20(JW Therapeutics)
NCT07024147
/ Not yet recruitingPhase 1IIT
An Open-Label, Single-arm Study of JWCAR239 in the Treatment of Relapse / Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
100 Clinical Results associated with CAR transduced autologous T cells targeting CD19/CD20(JW Therapeutics)
Login to view more data
100 Translational Medicine associated with CAR transduced autologous T cells targeting CD19/CD20(JW Therapeutics)
Login to view more data
100 Patents (Medical) associated with CAR transduced autologous T cells targeting CD19/CD20(JW Therapeutics)
Login to view more data
100 Deals associated with CAR transduced autologous T cells targeting CD19/CD20(JW Therapeutics)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Large B-Cell LymphomaPhase 1
China
JW Therapeutics (Shanghai) Co., Ltd.JW Therapeutics (Shanghai) Co., Ltd.
01 Jul 2025
Mantle-Cell LymphomaPhase 1
China
JW Therapeutics (Shanghai) Co., Ltd.JW Therapeutics (Shanghai) Co., Ltd.
01 Jul 2025
Marginal Zone B-Cell LymphomaPhase 1
China
JW Therapeutics (Shanghai) Co., Ltd.JW Therapeutics (Shanghai) Co., Ltd.
01 Jul 2025
Recurrent Grade 3b Follicular LymphomaPhase 1
China
JW Therapeutics (Shanghai) Co., Ltd.JW Therapeutics (Shanghai) Co., Ltd.
01 Jul 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free